Immunologic therapy for relapsing-remitting multiple sclerosis.

被引：6
作者：
MacLean H.J. [1 ]
Freedman M.S. [1 ]
机构：
[1] Multiple Sclerosis Clinic, University of Ottawa, Ottawa Hospital-General Campus, 501 Smyth Road, Ottawa
来源：
Current Neurology and Neuroscience Reports | 2001年 / 1卷 / 3期
关键词：
Multiple Sclerosis; Expand Disability Status Scale; Optic Neuritis; Glatiramer Acetate; Rebif;
D O I：
10.1007/s11910-001-0031-9
中图分类号：
学科分类号：
摘要：
The treatment of relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis, has been revolutionized in recent years. In addition to effective treatment of acute relapses, therapies are now available to prevent relapses, reduce the burden of disease as seen on magnetic resonance imaging, and possibly even slow the course of disease. There are now several agents either approved, awaiting approval, or in various stages of development in many countries. Evidence suggests that early intervention with these agents will yield the best results in the long run. The current approach to treatment of RRMS is the focus of this discussion.
引用
收藏
页码：277 / 285
页数：8
相关论文
共 116 条
  • [1] Schumacher GA(1965)Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis Ann NY Acad Sci 122 522-568
  • [2] Beebe G(1983)New diagnostic criteria for multiple sclerosis: guidelines for research protocols Ann Neurol 13 227-231
  • [3] Poser CM(1997)Primary progressive multiple sclerosis Brain 120 1085-1096
  • [4] Paty DW(1989)The natural history of multiple sclerosis: a geographically based study Brain 112 133-146
  • [5] Sheinberg L(1981)Clinical studies on multiple sclerosis. I. Presentation of an incidence material from Gothenburg Acta Neurol Scand 63 6-33
  • [6] Thompson AJ(2000)Relapses and progression of disability in multiple sclerosis N Engl J Med 343 1430-1438
  • [7] Polman CH(1998)Etiology and pathogenesis of multiple sclerosis Sem Neurol 18 287-293
  • [8] Miller DH(2000)Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann Neurol 47 707-717
  • [9] Weinshenker BG(1995)Transient immunomodulation by intravenous methylprednisolone treatment of multiple sclerosis Mult Scler 1 20-24
  • [10] Bass GP(1992)High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect J Neur Neurosurg Psychol 55 450-453
12345678910